Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P62D | ISIN: GB00BMVP7Y09 | Ticker-Symbol: RPD
Tradegate
05.09.25 | 21:54
30,700 Euro
-0,29 % -0,090
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ROYALTY PHARMA PLC Chart 1 Jahr
5-Tage-Chart
ROYALTY PHARMA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
30,50031,06006.09.
30,44031,05005.09.

Aktuelle News zur ROYALTY PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRoyalty Pharma prices $2B senior unsecured notes3
ROYALTY PHARMA Aktie jetzt für 0€ handeln
MiRoyalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes354WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900...
► Artikel lesen
MiRoyalty Pharma plc: Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes3
DiZenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab312WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of...
► Artikel lesen
DiZenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M2
DiRoyalty Pharma plc: Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million440Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab...
► Artikel lesen
25.08.Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales4
25.08.BeOne Medicines-Aktie steigt nach Lizenzdeal über 950 Millionen US-Dollar mit Royalty Pharma5
25.08.BeOne Medicines stock rises after $950 million royalty deal with Royalty Pharma5
25.08.Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne363WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) has acquired a royalty interest in Amgen's Imdelltra, a DLL3 targeting bispecific T-cell engager, from BeOne Medicines for $885 million upfront....
► Artikel lesen
25.08.Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million10
25.08.Royalty Pharma acquires Imdelltra royalty interest for $885 million2
25.08.Royalty Pharma to buy royalty interest in Amgen's Imdelltra for up to $950M9
25.08.Royalty Pharma plc: Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million277Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain...
► Artikel lesen
15.08.Dividendenbekanntmachungen (15.08.2025)14.038 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  A10 NETWORKS INC  US0021211018  0,06 USD  0,0514 EUR  AGCO CORPORATION  US0010841023  0,29 USD  0,2489 EUR  ALBEMARLE CORPORATION PREF...
► Artikel lesen
13.08.Royalty Pharma plc - 8-K, Current Report2
13.08.Royalty Pharma plc: Henry Fernandez Steps Down from Royalty Pharma's Board of Directors3
07.08.Royalty Pharma Plc Q2 Income Retreats450WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) released a profit for second quarter that Drops, from the same period last yearThe company's earnings came in at $30.17 million, or $0.07 per...
► Artikel lesen
06.08.Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model3
06.08.Royalty Pharma: BofA Securities hebt Kursziel nach starken Quartalszahlen an25
Weiter >>
80 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1